-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $33

Benzinga·03/06/2026 16:08:49
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $31 to $33.